

PROSTAGLANDINS AND CONGENERS XII.¹

THE SYNTHESIS OF dl-ERYTHRO AND dl-THREO-15,16-DIHYDROXYPROSTAGLANDINS

W. A. Hallett, A. Wissner, C. V. Grudzinskas, M. J. Weiss

Metabolic Disease Therapy Research Section, Lederle Laboratories,
American Cyanamid Company, Pearl River, New York 10965


An efficient first synthesis of all four dl-16-hydroxy-PGE₂ racemates via conjugate addition of functionalized vinyl cuprates to a cyclopentenone is presented. Compounds in the PGA₂ and PGF_{2α} series are also described.

















During the past several years our laboratory has been involved in the synthesis of prostaglandin congeners wherein the 15-hydroxy function is shifted to other positions along the β -chain. In previous reports we described the synthesis of congeners in which the hydroxy function has been placed at the C₁₃, C₁₆, C₁₇ or C₂₀ positions.² In particular, it was observed that a C₁₆-hydroxy group was consistent with important biological activity.² Accordingly it was of interest to prepare a congener containing both a C₁₅ and C₁₆ hydroxy group.

Our synthetic approach relies on the conjugate addition of appropriately functionalized vinyl cuprate reagents to the cyclopentenone 12. The precursor vinyl iodides 5 and 11 were prepared as outlined below.³ The reaction of 14 and valeraldehyde gave erythro 2 as the major stereoisomer.⁵ Removal of the THP group [EtOH:AcOH:H₂O, 2:1:1, 100°, 3 hr] followed by acetonide formation [(CH₃)₂C(OCH₃)₂, HClO₄, RT, 30 min] furnished 3. Hydrolysis of the TMS group [K₂CO₃, MeOH, 100°, 1 hr] provided 4, which after distillation (bp 103-106°/13 mm) was converted to erythro vinyl iodide 5 by the diisoamylborane procedure.⁷

For the synthesis of the vinyl iodide of the threo series, alcohol 2 was acetylated [Ac₂O, pyridine, 100°, 15 hr] to give 6. Removal of the THP group [EtOH:AcOH:H₂O, 2:1:1, 100°, 3 hr] and tosylation [TsCl, pyridine, 15 hr, RT] gave 7. Solvolysis of tosylate 7 [CaCO₃, H₂O, THF, reflux, 96 hr], followed by hydrolysis [KOH, H₂O, MeOH] of the resulting mixture of threo-acetates gave the threo-acetylenic diol 8, which was protected either as the bis-TMS derivative 9 [TMSCl, imidazole, DMF] or the acetonide 10 [(CH₃)₂C(OCH₃)₂, HClO₄]. Conversion of 9 to vinyl iodide 11 was accomplished by the diisoamylborane procedure.⁷

The vinyl iodides 5 and 11 were each exchanged with two equivalents of *t*-butyl lithium at -78° in ether to give the respective vinyl lithium derivatives, which on treatment with a solution of copper (I) thiophenoxide gave the corresponding vinyl cuprate reagents 13 and 14.⁸ Conjugate addition of these vinyl cuprate reagents to the bis-TMS protected cyclopentenone 13⁹ followed by removal of the protecting groups and silica-gel chromatography gave from 13 the erythro epimers 15 and 16 and from 14 the threo epimers 17 and 18.





Treatment of 15 and 16 with 1.5N hydrochloric acid in THF gave the respective PGA₂ analogs 19 and 20; reduction of 15-18 with lithium perhydro-9b-boraphenylhydride gave the respective PGF_{2α} derivatives 21-24.

The PGE₂ analogs 15-18 and the PGF_{2α} analogs 21-24 all show prostaglandin-like smooth muscle stimulating activity in the gerbil colon assay¹⁰ in the range 0.5%-14% of 2-PGE₁.

Acknowledgment. We wish to thank Mr. J. Baker and Dr. A. Streuli for certain chromatographic separations, Mr. L. Brancone and his staff for microanalyses and Messrs. W. Fulmor and G. Morton and Dr. R. T. Hargreaves, and staff for spectral data. We are grateful to Dr. J. E. Birnbaum and Miss R. Partridge for the gerbil colon data. We would also like to thank Dr. M. B. Floyd for many helpful discussions.

REFERENCES AND NOTES

1. For paper XI of this series see A. Wissner, submitted for publication.
2. (a) A. Wissner, submitted for publication; (b) M. B. Floyd, R. E. Schaub, and M. J. Weiss, Prostaglandins, 10, 289 (1975).
3. Satisfactory proton magnetic resonance, infrared, and C,H analytical or high resolution mass spectral data were obtained for the new compounds reported herein.
4. (a) H. Chwastek, R. Epsztein, and N. Le Goff, Tetrahedron, 29, 883 (1973); (b) H. Chwastek, N. Le Goff, R. Epsztein, and M. Baran-Marszak, Tetrahedron, 30, 603 (1974).
5. The erythro configuration of 2 was assigned on the basis of literature analogy^{4a} and on a comparison of the NMR spectra of acetonides 4 [$\delta_{\text{TMS}}^{\text{CDCl}_3}$, 4.72 (dd, 1H, H_a, J_{ab}=5.4 Hz); 4.08 (m, 1H, H_b)] and 10 [$\delta_{\text{TMS}}^{\text{CDCl}_3}$, 4.20 (dd, 1H, H_a, J_{ab}=8.0 Hz); 4.02 (m, 1H, H_b)] with model compounds.⁶
6. F. A. L. Anet, J. Amer. Chem. Soc., 84, 747 (1962).
7. A. F. Kluge, K. G. Untch, and J. H. Fried, J. Amer. Chem. Soc., 94, 7827 (1972).
8. C. J. Sih, J. B. Heather, R. Sood, P. Price, G. Peruzzotti, L. F. Hsu Lee, and S. S. Lee, J. Amer. Chem. Soc., 97, 865 (1975).
9. Compound 12 was prepared from the unprotected cyclopentenone [M. B. Floyd, Syn. Comm., 4, 317 (1974)] using hexamethyldisilazane-trimethylsilylchloride in pyridine.
10. J. R. Weeks, J. R. Schultz, and W. E. Brown, J. Appl. Physiol., 25 (6), 783 (1968).

(Received October 20, 1976)